Jesse L Berry1, Rima Jubran2, Kenneth Wong3, Thomas C Lee1, A Linn Murphree1, Jonathan W Kim1. 1. The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA. 2. The Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA. 3. Radiation Oncology Program, Children's Hospital Los Angeles, Los Angeles, California, USA.
Abstract
AIM: To evaluate clinical factors predictive of visual outcomes in Group D retinoblastoma eyes. METHODS: Retrospective chart review of patients with Group D retinoblastoma from January 2000 to December 2009. All patients were treated with systemic chemoreduction and external beam radiation as salvage therapy when indicated. Primary outcome measure was visual acuity. Clinical factors evaluated include quadrants of subretinal fluid, extent of vitreous seeding, involvement of more/less than 50% of the macula, endophytic/exophytic tumour classification, and presence of tumour behind the lens at diagnosis. RESULTS: Fifty-two Group D eyes of 41 patients were included; 10 eyes with visual acuity better than 20/80, 32 eyes with vision worse than 20/100 and 10 eyes with indeterminate vision (fix and follow). Complete retinal detachment (p=0.002), involvement of >50% of the macula (p=0.01), and seeding >3 quadrants (p=0.05) were associated with worse visual outcome. Average follow-up was 50.0 months (range: 10-118 months). CONCLUSIONS: At presentation, it is difficult to predict which Group D eyes will be salvaged with useful vision following systemic chemotherapy. The presence of complete retinal detachment, macular involvement and extensive seeding on presentation were factors associated with a worse visual prognosis in this study. These findings can guide the ophthalmologist in clinical decision making, as well as in counselling parents. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIM: To evaluate clinical factors predictive of visual outcomes in Group D retinoblastoma eyes. METHODS: Retrospective chart review of patients with Group D retinoblastoma from January 2000 to December 2009. All patients were treated with systemic chemoreduction and external beam radiation as salvage therapy when indicated. Primary outcome measure was visual acuity. Clinical factors evaluated include quadrants of subretinal fluid, extent of vitreous seeding, involvement of more/less than 50% of the macula, endophytic/exophytic tumour classification, and presence of tumour behind the lens at diagnosis. RESULTS: Fifty-two Group D eyes of 41 patients were included; 10 eyes with visual acuity better than 20/80, 32 eyes with vision worse than 20/100 and 10 eyes with indeterminate vision (fix and follow). Complete retinal detachment (p=0.002), involvement of >50% of the macula (p=0.01), and seeding >3 quadrants (p=0.05) were associated with worse visual outcome. Average follow-up was 50.0 months (range: 10-118 months). CONCLUSIONS: At presentation, it is difficult to predict which Group D eyes will be salvaged with useful vision following systemic chemotherapy. The presence of complete retinal detachment, macular involvement and extensive seeding on presentation were factors associated with a worse visual prognosis in this study. These findings can guide the ophthalmologist in clinical decision making, as well as in counselling parents. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Child health (paediatrics); Neoplasia; Vision
Authors: Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks Journal: JAMA Ophthalmol Date: 2017-11-01 Impact factor: 7.389
Authors: Rima F Jubran; Judith G Villablanca; Mark Krailo; Jin Piao; Li Huang; A Linn Murphree; Joan O'Brien; Dan Gombos; Carol L Shields; Anna Meadows; Murali Chintagumpala Journal: Pediatr Blood Cancer Date: 2020-06-26 Impact factor: 3.167
Authors: Angela Ferrario; Marian Luna; Natalie Rucker; Sam Wong; Ariel Lederman; Jonathan Kim; Charles Gomer Journal: PLoS One Date: 2016-04-06 Impact factor: 3.240
Authors: Ariana M Levin; Jasmine H Francis; Molly McFadden; Scott Brodie; Y Pierre Gobin; David H Abramson Journal: PLoS One Date: 2019-01-16 Impact factor: 3.240